

Evaluation of *in vitro* and *in vivo* Cytotoxic Activities and Kinase Inhibition of Newly Synthesized Cyclo (*N*^α-Dinicotinoyl)-Bis-[(L-Valinyl)-L-Lysine Methyl Ester]

A E Amr^{1,2}, M A Al-Omar², E A Elsayed^{3,4,*}, Mohammad E. Azab⁵ and Nermien M. Sabry²

¹ Pharmaceutical Chemistry Department, College of Pharmacy, Drug Exploration & Development Chair (DEDC), King Saud University, Riyadh 11451, Saudi Arabia.

² Applied Organic Chemistry Department, National Research Center, Cairo, Dokki 12622, Egypt.

³ Bioproducts Research Chair, Zoology Department, College of Science, King Saud University, Riyadh 11451, Kingdom of Saudi Arabia

⁴ Natural and Microbial Products Department, National Research Centre, Dokki, Cairo 12311, Egypt

⁵ Synthetic Organic Lab, Chemistry Department, Faculty of Science, Ain Shams University, Abbassia, Cairo 11566, Egypt

Received 9 November 2019; revised 13 October 2019; accepted 16 January 2020

Cancer is a major risk disease affecting human survival. The pharmaceutical companies are continuing searching for new drug candidates with promising anticancer activities, and reduced side effects. The current work aimed at synthesized a new tripeptide with potential pharmacological properties. L-Valine methyl ester was used to prepare cyclo (*N*^α-dinicotinoyl)-bis-[(L-valinyl)-L-lysine methyl ester]. The new compound revealed promising *in vitro* cytotoxic activities against different neuroblastoma, cervical carcinoma, fibrosarcoma as well as hepatocellular carcinomas. Furthermore, we also found that the obtained IC₅₀ of the compound decreased by about 50% during its *in vivo* anti-prostate cancer evaluation. Furthermore, the mechanism of action studies proposes that the new prepared derivative affects cancer cells through the inhibition of VEGFR-2 kinase enzyme.

Keywords: Macrocyclic tripeptidopyridine ester, *in vitro* cytotoxicity, *in vivo* antiprostatae, VEGFR-2 kinase activity

Introduction

Cancer is one of the most powerful mankind threatening disease, due to its high mortality rate as well as difficult treating procedures and harmful side effects^{1,2}. The pharmaceutical industry encourages continuous discovery of novel organic derivatives possessing potential anticancer activities, with the aim to combat cancer³. Heterocyclic ester derivatives have been identified as biologically significant components of medicinal chemistry¹, such as: antiviral, anti-inflammatory, antioxidant, anti-HIV, and anticancer agents^{4,5}. On the other hand, peptide candidates have been recognized as interesting exhibiting a broad spectrum of biological and pharmacological activities⁶⁻⁸. In view of these observations and in continuation of our previous work⁹⁻¹⁷ in heterocyclic and peptide chemistry, herein we reported the *in vitro* and *in vivo* cytotoxic activities and kinase inhibition of newly synthesized cyclo (*N*^α-dinicotinoyl)-bis-[(L-valinyl)-L-lysine methyl ester] derivative.

Materials and Methods

Synthesis of cyclo (*N*^α-dinicotinoyl)-bis-[(L-valinyl)-L-lysine methyl ester] (3)

Compound **3** was synthesized by reaction of 3, 5-pyridine dicarbonyl dichloride (**1**) with L-valine methyl ester followed by hydrolysis to corresponding diacid **2**, which was cyclized with L-lysine methyl ester by using Mixed anhydride method according to reported procedure. The tested compound **3** was previously characterized by physical and spectroscopic data which were reported by Amr *et al.*¹⁵.

Biological Activities

In vitro cytotoxicity screening

Various cancer cell lines (Table 1) were evaluated. Cells were cultivated and propagated using standard medium and conditions using standard cell culture protocols developed by our group¹⁸⁻²¹. After inoculation, plates were incubated at standard conditions for 24 h. After that, two plates/cell line, were fixed using TCA. Control references were dissolved in DMSO at comparable concentration doses. Plates were then processed as previously mentioned in the protocols. Absorbance was read at 515 nm and the IC₅₀ values were calculated from the regression analysis of the data.

*Author for Correspondence:
E-mail: eaelsayed@ksu.edu.sa

***In vivo* cytotoxic activity**

During this section, we used male Wistar rats obtained from the Animal House Colony, Research Institute of Ophthalmology, Giza, Egypt. Experiments were performed according to standard protocol²².

VEGFR-2 kinase activity assays by ELISA

This work was carried out according to standard protocol²³ using Sorafenibas a positive control. The absorbance was measured at 492 nm and IC₅₀ values were calculated from the inhibition rate percentage equation²³.

Results and Discussion**Chemistry**

Macrocyclic tripeptidopyridine candidate **3** was synthesized (Figure 1) and characterized by physical, chemical and spectroscopic evidences in advance according to our previous work¹⁹. In the current study,


we report the evaluation and activities of these compounds as possible anticancer agents.

Biological Screening**Screening of *in vitro* cytotoxic activities**

The cytotoxicity of the tested compounds was determined on seventeen different human cancer cell lines (Figure 2). Screening results showed that the prepared compound exhibited variable potentials against difference tested cancer cells. This is in accordance with our previous results obtained showing that different cells respond differently towards investigated drugs^{15,17-19}. This is due to differences between different cell types in terms of membrane structure and cell organization. Furthermore, comparing obtained results (in terms of IC₅₀ values) with those recorded for standard pharmaceutical drugs showed that comparable IC₅₀

Table 1 — Different cell lines and reference drugs used throughout the work

Cell line	Type	Cell line	Type	Cell line	Type
KB	Cervical carcinoma	U937	Leukemia	HeLa	Cervical carcinoma
SKOV-3	Ovarian carcinoma	K562	Leukemia	MCF-7	Breast carcinoma
SF-268	CNS cancer	G361	Melanoma	HT1080	Fibrosarcoma
NCI H460	Non-small lung cancer	SK-MEL-28	Melanoma	HepG2	Liver carcinoma
RKOP27	Colon adenocarcinoma	GOTO	Neuroblastoma	PC-3	Prostate carcinoma
HL60	Leukemia	NB-1	Neuroblastoma		
Reference drugs					
Sorafenib	Fluorouracil	Doxorubicin	Cytarabine		
Gemcitabine	Capecitabine	Aldesleukin	Paclitaxel		
Epirubicin	Imatinib	Bicalutamide	Flutamide		

Fig. 1 — Synthetic route for cyclo (N^α-dinicotinoyl)-bis-[(L-valinyl)-L-lysine methyl ester] **3**.




Fig. 2 — Cytotoxic activities of Cpd. 3 against different evaluated cell lines

values were obtained for colon adenocarcinoma (4.56 and 4.33 nM for compound **3** and Capecitabine, respectively), for the neuroblastoma NB-1 (6.0 and 5.15 nM for compound **3** and Doxorubicin, respectively), as well as the prostate cancer PC-3 cell line (9.76 and 8.22 nM for compound **3** and Bicalutamide, respectively). On the other hand, our prepared compound showed higher potential cytotoxic activities, where it showed almost 2-folds activity against the neuroblastoma GOTO cells (IC_{50} : 2.34 and 4.37 nM for compound **3** and Doxorubicin, respectively), 2.6-folds activity against HeLa cells (IC_{50} : 4.55 and 11.8 nM for compound **3** and Paclitaxel, respectively), 21-folds activity against the fibrosarcoma HT1080 (IC_{50} : 6.2 and 130.24 nM for compound **3** and Imatinib, respectively) and 5.5-folds activity against the HepG2 cells (IC_{50} : 6.2 and 34.4 nM for compound **3** and Gemcitabine, respectively).

In vivo activity

In vivo anti-prostate data showed potential anti-prostate activity for compound **3** in experimental

animal model. The obtained significant ED_{50} value observed for compound (**5**) ($5.26 \pm 0.034 \mu\text{M}$) was 2.2-folds higher than that obtained for the Flutamide reference drug ($11.6 \pm 0.09 \mu\text{M}$).

VEGFR-2 inhibition

Anti-VEGFR-2 results revealed that the synthesized compound (**3**) exhibited potent VEGFR-2 inhibitory activity, where the obtained IC_{50} value (1.91 nM) showed about 5% activity higher than the Sorafenib reference drug (2 nM).

Conclusion

Within the framework of the current investigation, we were able to synthesize a new cyclo (N^{α} -dinicotinoyl)-bis-[(L-valinyl)-L-lysine methyl ester from the reaction of dicarbonyl dichloride and L-valine methyl ester. The new derivative exhibited potent *in vitro* cytotoxic activities against neuroblastoma, cervical carcinoma, fibrosarcoma as well as hepatocellular carcinomas in comparison to standard

reference drugs. Furthermore, the new derivative showed 2.2-folds increased *in vivo* anti-prostate cancer activity, compared to control drug. These results support the potential use of the new derived tripeptide as a promising pharmaceutical molecule with potential *in vitro* and *in vivo* anticancer properties.

Abbreviations

IC₅₀ Half maximal inhibitory concentration

ED₅₀ Median effective dose

Acknowledgment

Authors are grateful to King Saud University for funding the work through Researchers Supporting Project (Project No. RSP-2019/66)".

References

- Denhart D J, Deskus J A, Ditta J L, Gao Q, King H D, Kozlowski E S, Meng Z, La Paglia M A, Mattson G K, Molski T F, Taber M T, Lodge N J, Mattson R J & Macor J E. Conformationally restricted homotryptamines. Part 5: 3-(trans-2-aminomethylcyclopentyl)-indoles as potent selective serotonin reuptake inhibitors. *Bio org Med Chem Lett*, **19**(2009) 4031-4033.
- Nothias-Scaglia L-F, Pannecouque C, Renucci F, Delang L, Neyts J, Roussi F, Costa J, Leyssen P, Litaudon M & Paolini J. Antiviral activity of diterpeneesters on Chikungunya virus and HIV replication. *J Nat Prod*, **78**(2015) 1277-1283.
- Wu X-W, Wei W, Yang X-W, Zhang Y-B, Xu W, Yang Y-F, Zhong G-Y, Liu H-N & Yang S-L. Anti-inflammatory phenolic acid esters from the roots and rhizomes of *Notopterygiumincisium* and their permeability in the human Caco-2 monolayer cell model. *Molecules*, **22** (2017) 935.
- Prudencio A, Faig J J, Song M J & Uhrich K E. Phenolic acid-based poly(anhydride-esters) as antioxidant biomaterials. *MacromolBiosci*, **16**(2016) 214-222.
- Orsolio N, Knezevic A H, Sver L, Terzic S & Basic I. Immunomodulatory and anti metastatic action of propolis and related polyphenolic compounds. *J Ethnopharmacol*, **94** (2004) 307-315.
- Koehbach J, Muttenthaler M, Gründemann C, Gruber C W. Pharmacological applications of natural peptide libraries. *BMC PharmacolToxicol*, **13** (2012)A31.
- Harnedy PA & Fitzgerald RJ. Bioactive peptides from marine processing waste and shellfish: A review. *J Funct Foods*, **4**(2012)6-24.
- Menezes IA, Barreto C, Antonioli ÂR, Santos MR & Sousa DP. Hypotensive activity of terpenes found in essential oils. *Z Naturforsch C Bio Sci*, **65**(2010) 562-566.
- Jung W-K, Mendis E, Je J-Y, Park P-J, Son BW & Kim HC. Angiotensin I-converting enzyme inhibitory peptide from yellowfin sole (*Limandaaspera*) frame protein and its antihypertensive effect in spontaneously hypertensive rats. *Food Chem*, **94**(2006)26-32.
- Al-Harbi NO, Bahashwan SA, Fayed AA, Aboonq MS & Amr AE. Anti-parkinsonism, hypoglycemic and antimicrobial activities of new poly fused ring heterocyclic candidates. *Int J Biol Macromol*, **57** (2013) 165-173.
- Ghozlan SA, Al-Omar MA, Amr AE, Ali K A & El-Wahab A A. Synthesis and antimicrobial activity of some heterocyclic 2,6-bis(substituted)-1,3,4-thiadiazolo-, oxadiazolo-, and oxathiazolidino-pyridine derivatives from 2,6-pyridine dicarboxylic acid dihydrazide. *J Heterocyc Chem*, **48** (2011) 1103-1110.
- Khalifa NM, Al-Omar MA, Amr AE, Baiuomy AR & Abdel-Rahman RF. Synthesis and biological evaluation of some novel fused thiazolo[3,2-a]pyrimidines as potential analgesic and anti-inflammatory agents. *Russ J Bio org Chem*, **41** (2015) 192-200.
- Hossan AS, Abu-Melha HM, Al-Omar MA & Amr A E. Synthesis and antimicrobial activity of some new pyrimidinone and oxazinone derivatives fused with thiophene rings using 2-chloro-6-ethoxy-4-acetylpyridine as starting material. *Molecules*, **17** (2012), 13642-13655.
- Mohamed S F, Youssef M M, Amr A E & Kotb E R. Antimicrobial activities of some synthesized pyridines, oxazines and thiazoles from 3-aryl-1-(2-naphthyl)prop-2-en-1-ones. *Sci Pharm*, **76** (2008) 279-303.
- Amr A E, Naglah A M, Sabry N M, Ibrahim A A, Elsayed E A & Attar A. Synthesis and investigation of 3,5-bis-linear and macrocyclic tripeptidopyridine candidates by using l-valine, N,N'-(3,5-pyridinediylldicarbonyl)bis-dimethyl ester as synthon. *Zeitschriftfür Naturforsch B*, **74** (2019) 473-478.
- Xi L, Zhang J, Liu Z, Zhang J, Yan J, Jin Y & Lin J. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking. *Org Bio mol Chem*, **11** (2013) 4367-4378.
- Amr A E, El-Naggar M, Al-Omar M A, Elsayed E A & Abdalla M M. *In vitro* and *in vivo* anti-breast cancer activities of some synthesized pyrazolonyl-estran-17-one candidates. *Molecules*, **23**(2018)1572.
- Amr A E, Abo-Ghalia M H, Moustafa G O, Al-Omar MA, Nossir E & Elsayed E A. Design, synthesis and docking studies of novel macrocyclic pentapeptides as anticancer multi-targeted kinase inhibitors. *Molecules*, **23**(2018) 2416.
- Wang D, Wang C, Gui P, Liu H, Khalaf S M, Elsayed E A, Wadaan M A, Hozzein W N & Zhu W. Identification, bioactivity, and productivity of actinomycins from the marine-derived *Streptomyces heliomycini*. *Fron Microbiol*, **8** (2017) 1147.
- El-Faham A, Elzatahry A, Al-Othman Z & Elsayed EA. Facile method for the synthesis of silver nanoparticles using 3-hydrazino-isatin derivatives in aqueous methanol and their antibacterial activity. *Int J Nanomed*, **9** (2014) 1167-1174.
- Elsayed E A, Sharaf-Eldin M A El-Enshasy H A & Wadaan M A. *In vitro* assessment of anticancer properties of *Moringa peregrina* essential seed oil on different cell lines. *Pak J Zoo*, **48** (2016) 853-859.
- Kinoyama I, Taniguchi N, Kawaminami E, Nozawa E, Koutoku H, Furutani T, Kudoh M & Okada M. N-Arylpiperazine-1-carboxamide derivatives: a novel series of orally active nonsteroidal androgen receptor antagonists. *Chem Pharm Bull*, **53** (2005) 402-409.
- Abd El-Galil E A, Elsayed E A, Al-Omar M A, BadrEldin H O, Nossier E S & Abdallah M M. Design, synthesis, anticancer evaluation and molecular modeling of novel estrogen derivatives. *Molecules*, **24** (2019) 416.